Stay updated on Tiragolumab Combo vs. Pembrolizumab in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Tiragolumab Combo vs. Pembrolizumab in Lung Cancer Clinical Trial page.

Latest updates to the Tiragolumab Combo vs. Pembrolizumab in Lung Cancer Clinical Trial page
- Check3 days agoChange DetectedStudy Record Dates now displays 'Last Update Posted (Estimated)' instead of 'Last Update Posted'; the underlying timestamp data are unchanged.SummaryDifference0.0%

- Check10 days agoChange DetectedNew study sites were added: New Cross Hospital, Wolverhampton, UK, and Adana Baskent University Medical Faculty, Adana, Türkiye. The total number of study locations is updated to 127, and related details such as the completion date and EU CTIS number were updated.SummaryDifference2%

- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedThe page now shows revision v3.3.2, replacing the previous revision v3.2.0.SummaryDifference0.0%

- Check38 days agoChange DetectedRemoved the site-wide notice about a lapse in government funding and the related operating-status guidance. The notice previously stated that information may not be up to date and directed users to cc.nih.gov and opm.gov for status updates.SummaryDifference0.2%

- Check61 days agoChange DetectedThe screenshots show the same study details page with no substantive differences in the study design, eligibility criteria, interventions, or outcomes; any differences appear to be minor or cosmetic edits that do not affect the page’s primary purpose. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check82 days agoChange DetectedCore content updated: a government funding and operating status notice has been added and the version updated to v3.2.0; the prior v3.1.0 tag was removed.SummaryDifference2%

Stay in the know with updates to Tiragolumab Combo vs. Pembrolizumab in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tiragolumab Combo vs. Pembrolizumab in Lung Cancer Clinical Trial page.